Literature DB >> 23487024

A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.

Amanda E Conway1, Paula B Scotland, Catherine P Lavau, Daniel S Wechsler.   

Abstract

The t(10;11) chromosomal translocation gives rise to the CALM-AF10 fusion gene and is found in patients with aggressive and difficult-to-treat hematopoietic malignancies. CALM-AF10-driven leukemias are characterized by HOXA gene up-regulation and a global reduction in H3K79 methylation. DOT1L, the H3K79 methyltransferase, interacts with the octapeptide/leucine zipper domain of AF10, and this region has been shown to be necessary and sufficient for CALM-AF10-mediated transformation. However, the precise role of CALM in leukemogenesis remains unclear. Here, we show that CALM contains a nuclear export signal (NES) that mediates cytoplasmic localization of CALM-AF10 and is necessary for CALM-AF10-dependent transformation. Fusions of the CALM NES (NES(CALM)-AF10) or NES motifs from heterologous proteins (ABL1, Rev, PKIA, APC) in-frame with AF10 are sufficient to immortalize murine hematopoietic progenitors in vitro. The CALM NES is essential for CALM-AF10-dependent Hoxa gene up-regulation and aberrant H3K79 methylation, possibly by mislocalization of DOT1L. Finally, we observed that CALM-AF10 leukemia cells are selectively sensitive to inhibition of nuclear export by Leptomycin B. These findings uncover a novel mechanism of leukemogenesis mediated by the nuclear export pathway and support further investigation of the utility of nuclear export inhibitors as therapeutic agents for patients with CALM-AF10 leukemias.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23487024      PMCID: PMC3674674          DOI: 10.1182/blood-2012-06-435792

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.

Authors:  Chi Wai So; Min Lin; Paul M Ayton; Everett H Chen; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

2.  Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins.

Authors:  Akiko Takeda; Nayan J Sarma; Anmaar M Abdul-Nabi; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2010-03-16       Impact factor: 5.157

3.  Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation.

Authors:  Ester Morgado; Stéphanie Albouhair; Catherine Lavau
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

Review 4.  Endocytosis and cancer: an 'insider' network with dangerous liaisons.

Authors:  Letizia Lanzetti; Pier Paolo Di Fiore
Journal:  Traffic       Date:  2008-08-14       Impact factor: 6.215

5.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Authors:  Parvathi Ranganathan; Xueyan Yu; Caroline Na; Ramasamy Santhanam; Sharon Shacham; Michael Kauffman; Alison Walker; Rebecca Klisovic; William Blum; Michael Caligiuri; Carlo M Croce; Guido Marcucci; Ramiro Garzon
Journal:  Blood       Date:  2012-06-07       Impact factor: 22.113

6.  Identification of nuclear export inhibitors with potent anticancer activity in vivo.

Authors:  Sarah C Mutka; Wen Qing Yang; Steven D Dong; Shannon L Ward; Darren A Craig; Pieter B M W M Timmermans; Sumati Murli
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family.

Authors:  M H Dreyling; J A Martinez-Climent; M Zheng; J Mao; J D Rowley; S K Bohlander
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lymphoid regulator Ikaros.

Authors:  P A Greif; B Tizazu; A Krause; E Kremmer; S K Bohlander
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

9.  MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.

Authors:  M H Dreyling; K Schrader; C Fonatsch; B Schlegelberger; D Haase; C Schoch; W Ludwig; H Löffler; T Büchner; B Wörmann; W Hiddemann; S K Bohlander
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

10.  The leukemia-associated-protein (LAP) domain, a cysteine-rich motif, is present in a wide range of proteins, including MLL, AF10, and MLLT6 proteins.

Authors:  V Saha; T Chaplin; A Gregorini; P Ayton; B D Young
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

View more
  15 in total

1.  DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia.

Authors:  Lucia Brandimarte; Roberta La Starza; Valentina Gianfelici; Gianluca Barba; Valentina Pierini; Danika Di Giacomo; Jan Cools; Loredana Elia; Antonella Vitale; Luigiana Luciano; Antonella Bardi; Sabina Chiaretti; Caterina Matteucci; Giorgina Specchia; Cristina Mecucci
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

2.  Effects of iron depletion on CALM-AF10 leukemias.

Authors:  Catherine P Lavau; Daniel S Wechsler; Jessica L Heath; Joshua M Weiss
Journal:  Exp Hematol       Date:  2014-09-03       Impact factor: 3.084

3.  Modulation of PICALM Levels Perturbs Cellular Cholesterol Homeostasis.

Authors:  Jacob L Mercer; Joseph P Argus; Donna M Crabtree; Melissa M Keenan; Moses Q Wilks; Jen-Tsan Ashley Chi; Steven J Bensinger; Catherine P Lavau; Daniel S Wechsler
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

4.  The ∼ 16 kDa C-terminal sequence of clathrin assembly protein AP180 is essential for efficient clathrin binding.

Authors:  Ling-Shan Chan; Lia Moshkanbaryans; Jing Xue; Mark E Graham
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

5.  Nuclear export signal within CALM is necessary for CALM-AF10-induced leukemia.

Authors:  Mai Suzuki; Kazutsune Yamagata; Mika Shino; Yukiko Aikawa; Koichi Akashi; Toshio Watanabe; Issay Kitabayashi
Journal:  Cancer Sci       Date:  2014-02-13       Impact factor: 6.716

6.  A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias.

Authors:  A E Conway; J M Haldeman; D S Wechsler; C P Lavau
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

7.  A Novel β-adaptin/c-Myc Complex Formation Modulated by Oxidative Stress in the Control of the Cell Cycle in Macrophages and its Implication in Atherogenesis.

Authors:  Victor García-González; Jaime Mas-Oliva
Journal:  Sci Rep       Date:  2017-10-18       Impact factor: 4.379

8.  A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.

Authors:  Bo-Rui Chen; Anagha Deshpande; Karina Barbosa; Maria Kleppe; Xue Lei; Narayana Yeddula; Pablo Sánchez Vela; Alexandre Rosa Campos; Robert J Wechsler-Reya; Anindya Bagchi; Soheil Meshinchi; Connie Eaves; Irmela Jeremias; Torsten Haferlach; David A Frank; Ze'ev Ronai; Sumit Chanda; Scott A Armstrong; Peter D Adams; Ross L Levine; Aniruddha J Deshpande
Journal:  Blood       Date:  2021-06-17       Impact factor: 25.476

9.  The Biochemical Properties and Functions of CALM and AP180 in Clathrin Mediated Endocytosis.

Authors:  Lia Moshkanbaryans; Ling-Shan Chan; Mark E Graham
Journal:  Membranes (Basel)       Date:  2014-07-31

10.  A Novel Sequence in AP180 and CALM Promotes Efficient Clathrin Binding and Assembly.

Authors:  Lia Moshkanbaryans; Jing Xue; Jesse Ray Wark; Phillip James Robinson; Mark Evan Graham
Journal:  PLoS One       Date:  2016-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.